source
- BioMarin signs up to $475 million licensing deal for new Fabry disease enzyme therapyBioMarin announced a licensing agreement to acquire rights to a long‑acting enzyme replacement therapy candidate for Fabry disease, paying $70 million upfront and up to $405 million in development…
- Biopharma manufacturing cuts slated to affect over 4,000 workers, with BioNTech leading layoffsCompanies investing billions to reshore drug production are trimming staff at manufacturing sites, with ten biotech and pharma firms planning cuts that could affect more than 4,000 employees. BioN…